RNS Number : 0666F
N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, is pleased to announce the filing of its Patent Cooperation Treaty (“PCT”) patent application for its sildenafil reformulation and provide an update on the work done by the Company in the year to date as it moves towards clinical trials. In addition, the Company is pleased to announce the filing of two new patents expanding its potential reformulation product pipeline to five.
Welcome to Steve Shares. This publication is an interactive weekly update on what’s happening over social media and the trending stocks that have made the news this week. I highlight and comment on the coming news and events in connection with the trending stocks. I also provide a round up of Share Talk’s key company interviews over the last week.
Steve Larratt, Share Research Business Analyst at Share Talk, presents the outlook for Rockhopper Exploration PLC (RKH.L) and N4 Pharma PLC (N4P.L). Steve talks to Tip TV’s Zak Mir.
N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, is pleased to announce the readmission today of the Company’s ordinary shares to trading on AIM and the commencement of dealings in the New Ordinary Shares under the ticker N4P (“Admission”).
Share Talk took the opportunity to speak with N4 Pharma’s Founder and CEO Nigel Theobald following their admission and first day of shares being available for dealing on AIM .
Closing 2015 the small cap markets took a keen interest in shell companies predominantly listed on AIM, I believe this has been born out of change.